|3.97||0||0.00||Vol 349.13K||1Y Perf 89.95%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||4.33||Analyst Rating||Strong Buy 1.50|
|Potential %||9.07||Finscreener Ranking||★★ 46.44|
|Insiders Trans % 3/6/12 mo.||-/-100/23||Value Ranking||★ 41.31|
|Insiders Value % 3/6/12 mo.||-/-100/-41||Growth Ranking||★+ 38.63|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-23||Income Ranking||— -|
|Market Cap||284.33M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||99.14||Earnings Date||11th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th May 2021|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||532.97K|
|Avg. Monthly Volume||625.99K|
|Avg. Quarterly Volume||1.16M|
CRH Medical Corporation of Beneficial Interest (AMEX: CRHM) stock closed at 3.97 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 349.13K shares and market capitalization of 284.33M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 155 people. CRH Medical Corporation of Beneficial Interest CEO is Tushar M. Ramani.
The one-year performance of CRH Medical Corporation of Beneficial Interest stock is 89.95%, while year-to-date (YTD) performance is 70.39%. CRHM stock has a five-year performance of 24.06%. Its 52-week range is between 1.66 and 3.99, which gives CRHM stock a 52-week price range ratio of 99.14%
CRH Medical Corporation of Beneficial Interest currently has a PE ratio of -11.30, a price-to-book (PB) ratio of 5.25, a price-to-sale (PS) ratio of 3.59, a price to cashflow ratio of 7.80, a PEG ratio of 2.32, a ROA of -11.86%, a ROC of -1.58% and a ROE of -35.78%. The company’s profit margin is -26.35%, its EBITDA margin is 11.40%, and its revenue ttm is $79.30 Million , which makes it $1.11 revenue per share.
Of the last four earnings reports from CRH Medical Corporation of Beneficial Interest, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. CRH Medical Corporation of Beneficial Interest’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for CRH Medical Corporation of Beneficial Interest is Strong Buy (1.5), with a target price of $4.33, which is +9.07% compared to the current price. The earnings rating for CRH Medical Corporation of Beneficial Interest stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRH Medical Corporation of Beneficial Interest has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRH Medical Corporation of Beneficial Interest has a Buy technical analysis rating based on Technical Indicators (ADX : 38.26, ATR14 : 0.09, CCI20 : 4.43, Chaikin Money Flow : 0.33, MACD : 0.27, Money Flow Index : 49.11, ROC : -0.77, RSI : 77.25, STOCH (14,3) : 36.36, STOCH RSI : 0.28, UO : 59.09, Williams %R : -63.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRH Medical Corporation of Beneficial Interest in the last 12-months were: David A. Johnson (Buy at a value of $96 756), Ian Webb (Sold 25 000 shares of value $72 500 ), James Kreger (Option Excercise at a value of $0), James Kreger (Sold 14 912 shares of value $44 726 ), Richard K. Bear (Option Excercise at a value of $0), Richard K. Bear (Sold 40 000 shares of value $114 200 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.